Development of plasma cell leukemia in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate

J Cancer Res Ther. 2018 Oct-Dec;14(6):1431-1433. doi: 10.4103/0973-1482.192762.

Abstract

Plasma cell leukemia (PCL) is a rare and an aggressive form of plasma cell dyscrasias. We report a 67-year-old male with PCL which developed while on imatinib mesylate (IM) therapy 38 months after diagnosis of chronic myeloid leukemia (CML). The patient has been treated successfully with bortezomib, melphalan and prednisolone. To our knowledge, only one case of PCL superimposed on Philadelphia positive CML has been reported in the literature and this was before the IM era.

Keywords: Chronic myeloid leukemia; plasma cell leukemia; tyrosine kinase inhibitors.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Humans
  • Imatinib Mesylate / therapeutic use*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
  • Leukemia, Plasma Cell / pathology*
  • Male
  • Protein Kinase Inhibitors / therapeutic use*

Substances

  • Protein Kinase Inhibitors
  • Imatinib Mesylate